Sunrise
Evaluate the Safety of TOL-3021 in Patients With New Onset or Established diagnosis of Type 1 diabetes within 5 years of screening.

Type of Study:
Type 1 diabetes patients who are 18 – 40 years

Study Length:
52 Weeks

Target Age/Sex:
18 – 40 years, Male and Female

Benefits:
Participants will receive at no cost: study product, study materials and study-specific procedures

Link: ClinicalTrials.gov

Staus: Closed

Description:

The SUNRISE study is a prospective, multi-center, double-blind, randomized, placebo-controlled trial in subjects aged 18.0 to <41.0 years diagnosed with T1D within 5 years.

This Study is Closed.